Conferences - Duke Hematologic Malignancy Program ::

Conferences

Duke Debates | Tumor Board | Duke Debates Archive

ARCHIVES FROM PRIOR CONFERENCES

Duke Debates - Controversies in the Management of Patients with Hematologic Malignancies

Each year, the Duke Hematologic Malignancy Program holds a national conference with experts from Duke and around the world coming together to debate the best new approaches to the care of patients with hematologic malignancies. Primary Oncologists, sub specialists, nurses, pharmacists and support staff all benefit from this unique format which encourages audience participation in these timely discussions.

2006 Duke Debates

April 7-8th
The Grove Park Inn, Asheville, NC

2005 Duke Debates

February 4-6 th
The Homestead , Hot Springs , Va.

Conference brochure

Program

Friday, February 4, 2005

11:15am-12:25pm
        Lunch / Registration

12:25pm-12:30pm        Opening Remarks- David Rizzieri, MD
Adjuvant / Supportive Care Moderator:       Brice Weinberg, MD
12:30-1:30 pm Debate- Quagmire of Coagulation:  All cancer patients with DVT should  receive thrombolytics and All cancer patients with DVT should receive heparin rather than warfarin       Tom Ortel, MD, PhD vs Stephan Moll, MD

1:30-2:10 pm
          Debate – All patients undergoing leukemia induction should be on fungal prophylaxis

Aimee Zaas vs Nelson Chao, MD

2:10-2:55 pm       Debate: Positive PET scan following induction
chemotherapy (prior to radiotherapy) should change treatment strategy in early stage patients with HD   Lou Diehl, MD vs Robert Prosnitz, MD

2:55-- 3:05 pm       Break

Monoclonal Antibody and Small molecule Therapies in
Lymphoma Moderator:             Jon Gockerman, MD
3:05-3:45 pm Use of Monoclonal Antibodies for the  Treatment of Lymphoma

Jon Gockerman, MD

3:40-4:10 pm  Radiolabeled immunotherapy- Bexxar :

Dr Kaminski

4:10-4:40 pm Radiolabeled immunotherapy- Zevalin:

Joe Moore, MD

4:40 - 5:00 pm Safe Strategy for Outpatient Delivery of  Radiolabeled Antibody Therapy : Patty Davis, Heather Brumbaugh

5:00-5:15 pm
        Overview of Antibody and small molecule protocols at Duke and panel discussion; David Rizzieri, MD

Free evening

Saturday, February 5, 2005

7:00-7:55 am
        Breakfast / Registration

7:55-8:00 am         Opening Remarks- David A. Rizzieri, MD

Myeloma Moderator:             Cristina Gasparetto, MD
8:00-8:45 am          Debate- thalidomide induction therapies vs non-thalidomide options

Carlos Decastro, MD vs Cristina Gasparetto, MD

8:45-9:20 am          Options for care in patients with refractory   myeloma with case presentation

Cristina Gasparetto, MD

9:20-10:10 am         Debate-Total Treatment Therapy vs non-    myeloablative allogeneic transplantation at first response Raymond Thertulien, MD, PhD vs Cristina Gasparetto, MD
10:10-10:15 am  Overview of Protocol options for myeloma at  Duke ;     Cristina Gasparetto, MD

10:15 - 10:25 am     Break
Leukemia Moderator:             John Chute, MD
10:25-11:00 am Therapy of AML in Those over 60 Years of Age ;  Joseph O. Moore, MD/Patrick Buckley MD with case presentation

11:00-12:00 noon Debate - Gleevec vs Allogeneic Transplantation in Patients <40 Years Old : Arati Rao , MD vs Maureen Ross, MD, PhD

11:30-12:15 am Debate - Standard therapy vs
Allogeneic Transplantation for MDS Carlos Decastro, MD vs John McCarty , MD
12:15-1pm  Growth Factor Support in Patient’s with a Hematologic Malignancy :

The case for Neupogen Jeffrey Crawford, MD

  The Niche for Leukine Ed Waller, MD

1:00-1:10 pm    Overview of Protocol options for Leukemia at Duke ;   Joseph Moore, MD

1:10-2:10 pm             Lunch

6:00-11:00 pm      Dinner; skating rink reserved; live music/dancing afterwords

Sunday, February 6, 2005

7:00-7:55 am         Breakfast / Registration
7:55-8:00 am         Opening Remarks- David A. Rizzieri, MD
Lymphoma Moderator:             Yiping Yang , MD
8:00-8:45 am  Debate- Autologous vs Allogeneic transplantation for relapsed follicular lymphoma

   Deb Frei-Lahr, MD vs Mitch Horwitz, MD

8:45-9:25 am         Debate- Radiotherapy is not needed in patients with lymphoma involving the CNS Lillian Burke, MD vs Leonard Prosnitz

9:25- 9:55 am        New avenues of therapy using Rituximab ;     Andrew Zelenetz, MD PhD

9:55-10:05 am      Break

10:05-10:35 am     Liposomal Vincristine data ;                                Alma Rodriguez, MD

10:35-11:20 am        Standard dose therapies vs nonmyeloablative transplantation for CLL

Bayard Powell MD vs Jon Chute, MD

11:20-11:40 am  Overview of Protocol options for lymphoma at Duke ;      Lou Diehl, MD

11:40-12:30 am      Tumor Board , panel discussion       Selected case presentations from participants Moderator: Joe Moore, MD/ Patrick  Buckley MD
12:30-12: 40 pm     Summary and CME record keeping, Adjourn

2004 Duke Debates
April 2-3rd
The Biltmore, Asheville, NC

Conference Mailer (

- 308KB)
Conference Brochure

Program (

- 98KB)

Friday, April 2, 2004

11:15am-12:25pm
        Lunch / Registration
12:25pm-12:30pm       Opening Remarks- David Rizzieri, MD
Adjuvant / Supportive Care
Moderator:            Keith Sullivan, MD
12:30-1:10 pm        Bisphosphonates for Supportive Care of the
                             Myeloma Patient
                              Gwynn Long, MD

1:15-2:00 pm Debate - Prophylaxis vs Active Treatment of

Fungal Infections in the Immunosuppressed

Population

Aimee Zaas vs John Serody, MD

2:05-2:45 pm Growth Factor Support in the Patient with a

Hematologic Malignancy

Jeffrey Crawford, MD

2:45-2:55 pm Break

Monoclonal Antibody Therapy in Lymphoma
Moderator:            Leonard Prosnitz, MD
2:55-3:40 Debate - Adjuvant Radiation Therapy for
                             Advanced Stage HD or DLCL NHL
                              Robert Prosnitz, MD vs Jon Gockerman, MD

3:45-4:40 Use of Monoclonal Antibodies for the

Treatment of Lymphoma

Dave Rizzieri , MD

4:45-5:15 Safe Strategy for Outpatient Delivery of

Radiolabeled Antibody Therapy

Donna Adams, Traci Foster, Patty Davis, Liz

Anderson

5:30-6:30 Reception

Saturday, April 3, 2004
7:00-7:50 am        Breakfast / Registration
7:50-7:55 am        Opening Remarks- David A. Rizzieri, MD
Myeloma
Moderator:            Lou Diehl, MD
7:55-8:25 am           Role of Thalidomide Analogs, Arsenic and
                              Other New Agents
                               Cristina Gasparetto, MD

8:30-9:05 am Proteosome Inhibitor Use in Myeloma

Robert Orlowski, MD

9:10-9:55 am Debate – VAD or Clinical Trials vs Auto

Transplant for Newly Diagnosed Myeloma

Carlos DeCastro MD vs Cristina Gasparetto, MD

9:55 - 10:05 am Break

Leukemia
Moderator: Jon Gockerman, MD

10:05-10:35 am Therapy of AML in Those over 60 Years of Age

Joseph O. Moore, MD

10:40 - 11:25 am Debate - Gleevec vs Allogeneic Transplantation

in Patients <40 Years Old

Joseph O. Moore, MD vs Nelson Chao, MD

11:30 - 12:15 am Debate - MDS Supportive Care vs Clinical

Trials with Thalidomide or Arsenic vs

Allogeneic Transplantation for MDS

Carlos DeCastro, MD vs Mitch Horwitz, MD

12:15-1:30 Lunch

Lymphoma
Moderator:            Yiping Yang, MD
1:30-2:15 CLL: Chlorambucil or Fludarabine vs
                            Combination Therapies for CLL
                              Kanti Rai, MD

2:20- 3:05 Debate- Treatment of Newly Diagnosed

Follicular Lymphoma: Vaccine vs CHOP-R vs

Single Agent therapies

Jon Gockerman, MD vs Len Prosnitz

3:05-3:45 Novel Approaches to the Treatment of Mantle

Cell Lymphoma

David Rizzieri, MD

3:45-3:50 Summary and CME record keeping